2018ILROG指南：成人纵隔淋巴瘤的质子治疗.pdf

From by guest on October 22, 2018. For personal use only. Special Report Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines Bouthaina Shbib Dabaja,1 Bradford S. Hoppe,2 John P. Plastaras,3 Wayne Newhauser,4 Katerina Rosolova,5,6 Stella Flampouri,2 Radhe Mohan,7 N. George Mikhaeel,8 Youlia Kirova,9 Lena Specht,10 and Joachim Yahalom11 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; 2 Department of Radiation Oncology, University of Florida, Jacksonville, FL; 3 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA; 4 Department of Radiation Physics, University of Louisiana, Baton Rouge, LA; 5 Proton Therapy Department, Proton Therapy Center Czech, Prague, Czech Republic; 6 Department of Oncology, Charles University in Prague and Motol University Hospital, Prague, Czech Republic; 7Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX; 8Department of Radiation Oncology, Guy’s and St. Thomas’ Hospital, London, United Kingdom; 9 Department of Radiation Oncology, Institut Curie, Paris, France; 10Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; and 11Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Among adult lymphoma survivors, radiation treatment tech- especially the risks for cardiac morbidity and second cancers. niques that increase the excess radiation dose to organs at Because proton therapy may have some disadvantages, iden- risk (OARs) put patients at risk for increased side effects, tifying the patients and the circumstances that may benefit especially late toxicities. Minimizing radiation to OARs